Despite A 4x Rise, Editas Medicine May Continue To Trend Higher
- Friday, January 15, 2021, 7:13
- Market
- Add a comment
Despite a stellar 4x rise since the March 23 lows of last year, at the current price of around $73 per share we believe Editas Medicine, a biotechnology company focused on developing treatments using gene editing technology, looks attractive and it can see more upside from the current levels…
About the Author
admin123 has written 23544 stories on this site.
